Mega Genomics (HKSE:06667) FCF Margin % : 139.27% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mega Genomics's Free Cash Flow for the six months ended in Dec. 2023 was HK$79.9 Mil. Mega Genomics's Revenue for the six months ended in Dec. 2023 was HK$57.3 Mil. Therefore, Mega Genomics's FCF Margin % for the quarter that ended in Dec. 2023 was 139.27%.

As of today, Mega Genomics's current FCF Yield % is 6.09%.

The historical rank and industry rank for Mega Genomics's FCF Margin % or its related term are showing as below:

HKSE:06667' s FCF Margin % Range Over the Past 10 Years
Min: -8.3 Med: 29.52 Max: 84.33
Current: 84.33

During the past 5 years, the highest FCF Margin % of Mega Genomics was 84.33%. The lowest was -8.30%. And the median was 29.52%.

HKSE:06667's FCF Margin % is ranked better than
99.54% of 219 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.13 vs HKSE:06667: 84.33

Mega Genomics FCF Margin % Historical Data

The historical data trend for Mega Genomics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics FCF Margin % Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

29.52

50.09

11.05

-8.30

84.33

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			24.73	-28.97	33.63	55.20	139.27

Competitive Comparison of Mega Genomics's FCF Margin %

For the Diagnostics & Research subindustry, Mega Genomics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Genomics's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mega Genomics's FCF Margin % falls into.

Mega Genomics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mega Genomics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	139.552	/	165.489
	=	84.33 %

Mega Genomics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	79.855	/	57.337
	=	139.27 %

Mega Genomics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mega Genomics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics (HKSE:06667) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet consumers' growing preventive medical needs.

Executives

Guo Meiling	2101 Beneficial owner
Lin Lin	2101 Beneficial owner
Yu Rong	2501 Other
Infinite Galaxy Health Limited	2101 Beneficial owner
Mei Nian Investment Limited	2101 Beneficial owner
Kastle Limited	2501 Other
Mega Marvelous Limited	2501 Other
Yurong Technology Limited	2101 Beneficial owner
Niu Zhencai	2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Mega Genomics (HKSE:06667) Headlines

No Headlines